Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/51516
Title: NESSCA Validation and Responsiveness of Several Rating Scales in Spinocerebellar Ataxia Type 2
Authors: Monte, Thais L.
Reckziegel, Estela R.
Augustin, Marina C.
Silva, Amanda S. P.
Locks-Coelho, Lucas D.
Barsottini, Orlando [UNIFESP]
Pedroso, Jose L. [UNIFESP]
Vargas, Fernando R.
Saraiva-Pereira, Maria-Luiza
Leotti, Vanessa Bielefeldt
Jardim, Laura Bannach
Keywords: Neurological Examination Score for Spinocerebellar Ataxia
NESSCA
SARA
SCAFI
SCA2
Spinocerebellar ataxia type 2
Issue Date: 2017
Publisher: Springer
Citation: Cerebellum. New York, v. 16, n. 4, p. 852-858, 2017.
Abstract: Spinocerebellar ataxia type 2 (SCA2), caused by a CAG expansion (CAGexp) at ATXN2, has a complex clinical picture. While validated ataxia scales are available, comprehensive instruments to measure all SCA2 neurological manifestations are required. This study aims to validate the Neurological Examination Score for the assessment of Spinocerebellar Ataxias (NESSCA) to be used in SCA2 and to compare its responsiveness to those obtained with other instruments. NESSCA, SARA, SCAFI, and CCFS scales were applied in symptomatic SCA2 patients. Correlations were done with age at onset, disease duration, CAGexp, and between scales. Responsiveness was estimated by comparing deltas of stable to worse patients after 12 months, according to Patient Global Impression of change, and the area under the curve (AUC) of the Receiver Operating Characteristics curve of scores range. Eighty-eight evaluations (49 patients) were obtained. NESSCA had an even distribution and correlated with disease duration (r = 0.55), SARA (r = 0.63), and CAGexp (rho = 0.32): both explained 44% of NESSCA variance. Deltas (95% CI) after 1 year in stable and worse patients were only significantly different for SARA. NESSCA, SARA, SCAFI, and CCFS AUC were 0.63, 0.81, 0.49, and 0.48, respectively. NESSCA is valid to be used in SCA2. However, the only instrument that presented good responsiveness to change in 1 year was SARA. We suggest that NESSCA can be used as a secondary outcome in future trials in SCA2 due to the burden of neurological disabilities related to disease progression.
URI: http://repositorio.unifesp.br/handle/11600/51516
ISSN: 1473-4222
Other Identifiers: http://dx.doi.org/10.1007/s12311-017-0855-8
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.